Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Return on Sales (2016 - 2025)

Heron Therapeutics' Return on Sales history spans 13 years, with the latest figure at 0.0% for Q4 2025.

  • For Q4 2025, Return on Sales fell 10.0% year-over-year to 0.0%; the TTM value through Dec 2025 reached 0.02%, up 6.0%, while the annual FY2025 figure was 0.07%, 3.0% up from the prior year.
  • Return on Sales reached 0.0% in Q4 2025 per HRTX's latest filing, up from 0.11% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.1% in Q4 2024 to a low of 2.69% in Q2 2021.
  • Average Return on Sales over 5 years is 1.04%, with a median of 0.74% recorded in 2022.
  • Peak YoY movement for Return on Sales: tumbled -53bps in 2021, then soared 191bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 2.59% in 2021, then soared by 74bps to 0.68% in 2022, then surged by 56bps to 0.3% in 2023, then skyrocketed by 134bps to 0.1% in 2024, then plummeted by -99bps to 0.0% in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Return on Sales are 0.0% (Q4 2025), 0.11% (Q3 2025), and 0.04% (Q2 2025).